Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure

Use of Near Infrared Spectroscopy in Preterm Infants to Determine Patent Ductus Arteriosus Closure Following Medical Treatment

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03026192

Enrollment

Registered

2017-01-20

Start date

2016-12-31

Completion date

2018-06-30

Last updated

2019-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patent Ductus Arteriosus

Brief summary

Using cerebral and renal near infrared spectroscopy monitoring to determine PDA closure in preterm infants after completing medical treatment for a hemodynamically significant PDA.

Interventions

DEVICEnear infrared spectroscopy

Near infrared spectroscopy will be placed on infants both with and without hsPDA

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Minutes to 1 Weeks

Healthy volunteers

Yes

Inclusion criteria

* preterm infants less than 32 weeks gestation

Exclusion criteria

* infection, congenital heart disease, syndromic anomalies, and perinatal asphyxia.

Design outcomes

Primary

Measure	Time frame
Change in NIRS readings	3 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026